Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Compliance Corner: Must Employee Notify Lab of DUI?
QUESTION If one of our employees gets a DUI, do they have to notify us? ANSWER It depends. EXPLANATION There are at least four factors affecting whether the employee would have to come forward and tell you about the DUI? Your HR policies: What, if anything, do your...
Marketing Pitfalls to Avoid: Deceptive Advertising—the Other Kind of “False Claims”
We all know that marketing activity is a breeding ground for potential lab liability. But while most labs are sensitive to the risks posed by the Antikickback Statute, Stark Law and False Claims Act, federal false advertising laws may fly under the radar. Here’s a...
Pay rates, vacations while recovering, gig economy
Department of Labor enters final stage of update to ‘regular rate’ rule under FLSA. As we have discussed previously in these updates, the Department of Labor has been working to update the definition
FDA Watch: Agency Resounds the Alarm on Biotin Test Interference
In early November 2019, the U.S. Food and Drug Administration (FDA) updated a previous safety communication about the potential of biotin to significantly interfere with diagnostic tests. The update reiterates the warning
FDA Unveils New Process for Streamlined Review of IVD Tests Used in Cancer Drug Trials
Typically, in vitro diagnostic (IVDs) tests used in investigational cancer drug trials require two submissions: one for the IVD test and another for the drug. But on Oct. 9, 2019, the US Food and Drug Administration (FDA) issued final guidance setting out a streamlined process that allows companies to apply